New Schizophrenia Drug Shows Promise In Phase II Human Trials
New Schizophrenia Drug Shows Promise In Phase II Human Trials
|
A new experimental drug for the treatment of schizophrenia which targets glutamate receptors in the brain rather than dopamine has shown promise in human trials. The volunteers experienced significant improvements in their symptoms while suffering few side effects. The drug is currently called "LY2140023".You can read about this trial in an article published in Nature Medicine. [click link for full article] |
read more...
News entry number 468 added on Sep 3, 2007 in the Health category.
Comenteaza
Other News in the Health category
Categorie:
Categorie:
Categorie:
Categorie:
Categorie:
Related Links
- New Schizophrenia Drug Shows Promise in Trials
- Multiple flu vaccine shows promise in clinical trials, say its makers
- New Fox hunt: Network seeks shows that appeal to everyone
- Newspapers Report Medicaid Developments In Maryland, New York, Wisconsin
- New witness account shows Khadr charges should be dropped: lawyers
- Merck: Erbitux Phase III Study - FLEX Increases Overall Survival In First-line Treatment Of
- Dispatches From Iraq: Hunting Al Qaeda, Part II of III
- Motorola promises a wave of new products next month
- FDA Approves New Uses For Evista - Drug Reduces Risk Of Invasive Breast Cancer In Postmenopausal
News Categories
745
523
480
347
1011
693
280
973
Top 10 News
- Texas Woman Claims to Have Found Mythical 'Chupacabra'
- Google Starts Hosting News on Website
- Wireless technology hits security budgets
- Google forced to push image in China
- Western School Board limits digital devices
- 'Spooky' science points to quantum internet
- Nuñez, gov. gamble on healthcare overhaul
- Ho-hum, the guest's another candidate
- Study Focuses On Cancer Risk In Biologic Treatment For Rheumatoid Arthritis
- Microsoft purchase of RIM nice to consider, but unlikely
Statistics
News:
News Categories:
News Read:
News Categories:
News Read:
5052
8
610
8
610